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Abstract
Background: Data about the epidemiology of valvular heart disease (VHD) in the elderly is 
scarce. Hand-held ultrasound devices (HUDs) enable point-of-care ultrasound scanning 
(POCUS) but their use in an elderly population has not been reported for VHD screening in 
primary practice.
Methods: One hundred consecutive subjects aged >70 years without a VHD diagnosis had 
2D and colour Doppler POCUS by an accredited sonographer, using a contemporary HUD 
(Vscan), in a primary practice setting. Patients with left-sided valve pathology identified by 
Vscan were referred for formal echo in the local tertiary cardiac centre.
Results: Mean age (s.d.) was 79.08 (3.74) years (72–92 years); 61 female. By Vscan, we found 
five patients with ≥moderate aortic stenosis (AS), eight with ≥moderate mitral regurgitation 
(MR) and none with ≥moderate aortic regurgitation. In the AS and MR groups each, one 
patient had valve intervention following from the initial diagnosis by Vscan, two and one 
respectively are under follow-up in the valve clinic, while two and four respectively refused 
TTE or follow-up. Two patients with moderate MR by Vscan had mild and mild/moderate 
MR respectively by TTE and were discharged. Total cost for scanning 100 patients was 
$18,201 – i.e. $182/patient.
Conclusions: Screening with a hand-held scanner (Vscan), we identified 5/100 elderly 
subjects who needed valve replacement or follow-up in valve clinic, at a cost of  
$182/patient. These findings have potential significance for the allocation of resources in 
the context of an ageing population.
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Introduction
Heart valve disease is ‘the next cardiac epidemic’ (1) and 
imposes an increasing drain on health care resources 
(2). There are little data about the prevalence of heart 
valve disease in the old; in major published surveys 
(3, 4), elderly patients are a minority. An exception is the 
Ox-Valve study (5) which included only participants over 
the age of 65 years.
There has been an increase in life expectancy (6) at 
the same time with the advent of trans-catheter valve 
interventions. Previously inoperable patients have 
become candidates for interventional treatment (7, 8), 
and trans-catheter therapies may replace conventional 
valve surgery (9, 10). Understanding the burden of VHD 
in the old becomes essential for planning appropriate 
allocation of resources.
Echocardiography has been ‘democratised’ by the 
advent of pocket scanners (11). Their accuracy for the 
detection of common pathologies is well validated 
against high-end scanners (12, 13); they allow ultrasound 
examinations effectively anywhere, revolutionising 
screening for heart disease (14, 15).
We assessed the prevalence of left-sided heart valve 
disease in a cohort of adults aged 70  years and above, 
without a previous formal diagnosis of heart valve 
disease, by performing hand-held echocardiograms in 
primary practice.
Methods
Inclusion criteria and patient recruitment
Consecutive patients aged ≥70 years attending a primary 
health care provider, Swansea Bay Health, in Swansea, 
Wales, UK were eligible if they gave informed consent and 
if they had not received a formal diagnosis of heart valve 
disease or of heart failure before inclusion. Swansea Bay 
Health covers a population of about 75,000 in and around 
Swansea.
We recruited using posters and leaflets, available in 
the waiting area and in the consultation rooms, and we 
encouraged GPs to mention the study to eligible patients.
Patients in whom the Vscan found significant 
pathology were encouraged to attend the formal TTE 
in our tertiary centre (Morriston Cardiac Centre, 
Swansea, UK).
South East Coast – Surrey Research Ethics Committee 
had approved the study protocol.
Echocardiography and risk factors
Patients filled in a questionnaire about their cardiac risk 
factors, and then had a cardiac ultrasound examination. 
Parasternal long-, short-axis and apical four-chamber, 
two, three and five-chamber views were obtained in left 
lateral decubitus. We used the ASE recommendations 
(16) for POCUS. All scans were performed by one of the 
authors (CW), an experienced, BSE-accredited, hospital-
based cardiac physiologist, who visited the surgery 
1 day/week over 6 months and scanned all patients who 
had given informed consent for the study.
The Vscan (GE Vingmed Ultrasound, Horten, Norway) 
uses a phased-array probe with a frequency range of 
1.7–3.8 MHz; it weighs 390 g and fits inside a pocket. It 
displays grey-scale images with a fixed sector angle of 75°; 
the depth can be adjusted up to 25 cm; colour flow has 
a fixed box size and a fixed pulse repetition frequency. 
There are no spectral Doppler capabilities. Examinations 
were saved as one-beat loops on the micro-SD card of 
the device and were then downloaded on a desktop PC 
using proprietary software (Vscan Gateway, GE Vingmed 
Ultrasound). Formal TTE studies were performed on 
Philips iE33 or GE Vivid 7 machines in the BSE-accredited 
echocardiographic department of the Morriston Cardiac 
Centre, according to the BSE dataset.
Image analysis
Video loops of all the examinations were sent for analysis 
to an ESC-Accredited Laboratory (Prof B Popescu, ‘C 
Iliescu’ Cardiology Institute, Bucharest, Romania) and 
studies were reported by an experienced echo doctor (AM) 
blinded to clinical details of the patients. The following 
were assessed:
– Quality of images in the parasternal and apical views, 
and of the whole study, for each patient; graded as 
good, moderate, poor or uninterpretable;
– Aortic valve (AV):
Aortic stenosis:
 •  First, the core lab provided a qualitative classification 
of the appearance of the AV: normal, mild, moderate 
or severe AS;
• Then, AV calcification was assessed according to the 
scheme by Rosenhek et al. (17): 1, no calcification; 2, 
mildly calcified (small isolated spots); 3, moderately 
calcified (multiple larger spots) and 4, heavily calcified 
(extensive thickening and calcification of all cusps). 
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://erp.bioscientifica.com © 2019 The authors
 Published by Bioscientifica Ltdhttps://doi.org/10.1530/ERP-19-0011
Downloaded from Bioscientifica.com at 09/13/2019 09:15:11AM
via free access
C Williams et al. Screening for valve disease in 
the elderly
736:3
AV sclerosis was defined as thickening of the leaflets 
without restriction in their movement;
• Finally, AV cusp restriction was assessed using the 
method described by Abe et  al. for Vscan (18): 
we scored each cusp either as having normal 
mobility (score 0), restricted mobility (score 1) or 
severely restricted mobility (score 2) and calculated 
a restriction score for each valve by adding the 
individual scores of each leaflet;
AV regurgitation:
• Its presence and severity was evaluated qualitatively 
by integrating longitudinal and transverse extension 
of the jet into the LVOT.
– Mitral valve (MV):
• MV regurgitation: Its presence and severity was 
assessed qualitatively by assessment of the extent of 
the colour flow map of the regurgitant jet in the LA;
• MV stenosis: Defined qualitatively, by identifying 
restriction of cusp motion and/or paradoxical 
posterior leaflet movement in diastole;
– LVEF was evaluated by ‘eye-balling’ (normal, reduced, 
hyperdynamic), and wall-motion abnormalities were 
identified and described.
Statistics
We analysed the data using SPSS v.22 (SPSS), with chi-
square test for comparing proportions and an independent 
samples t-test for continuous variables; significance level 
was set at <0.05.
Follow-up
We invited patients with ≥moderate severity of left-sided 
valve disease by Vscan screening to have formal TTE in 
the hospital. We followed that with an appointment in 
the cardiology clinic, with appropriate referral (to the 
valve clinic for follow-up or to a cardiac surgeon for valve 
intervention).
Costs
We documented all the costs incurred during the study 
in UK pounds sterling (GBP, £), using prices and fees 
supplied by our finance department and rounded them to 
the nearest decimal point. We then converted the costs to 
euro (EUR, €) and to US dollars (USD, $), using Google’s 
online currency convertor (spot exchange rates as of 
15 April 2018: 1 GBP = 1.153 EUR; 1 GBP = 1.424 USD).
Results
We recruited 100 consecutive patients (61 female) 
between June and September 2015, mean age (s.d.) 79.08 
(3.74) years, range 72–92 years. Table 1 shows risk factors 
and clinical characteristics. This represents approximately 
1.4% of the total population aged 70 years and above in 
our catchment area (19).
Quality of Vscan studies
Poor quality studies were infrequent (7%), and overall the 
quality of the images was better from the parasternal than 
from the apical ‘window’.
Left-sided valve disease
By Vscan screening, we found five patients with at 
least moderate AS, eight with at least moderate MR and 
none with more than mild AR (Table 2). Restriction and 
calcification scores for the AV separated normal valves 
from visually stenosed valves (Table  3). There was one 
case of mild rheumatic mitral stenosis. In the AS and 
MR groups each, one patient had valve intervention, 
two and one respectively are now under follow-up in 
the valve clinic, while two and four respectively refused 
formal echo or follow-up in the valve clinic. Two patients 
in the MR group had mild MR by formal TTE and were 
discharged. Outcomes and concordance between Vscan 
Table 1 Clinical characteristics of the patients (n = 100).
Clinical feature Status Frequency/%
Angina N 95
Y 5
Hypertension N 58
Y 40
Unsure 2
Hypercholesterolaemia N 59
Y 41
Current smoking N 99
Y 1
Diabetes mellitus N 90
Y 10
Heart murmur N 97
y 2
Unsure 1
Atrial fibrillation N 94
Y 6
Warfarin N 96
Y 4
Bronchodilators N 84
Y 16
N, no; Y, yes.
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and formal TTE are summarised in Tables  4 and 5. 
Figures 1, 2 and 3 illustrate typical findings in patients 
with AS and MR.
Association with risk factors
Degenerative AS was more prevalent in patients with a 
history of angina (P < 0.01).
There were no other associations between left-sided 
heart valve lesions and clinical characteristics.
Costs
Hand-held ultrasound scans
Performing the 100 Vscan studies incurred a total cost 
of £5000 (€5765; $7121) in sonographer fees (50 × 100), 
£1000 (€1153; $1424) in transport costs for the sonographer 
(all patients attended the surgery by their own means of 
transportation), £800 (€922; $1139) reporting fee to the 
core lab, and £5500 (€6341; $7833) in capital costs, that 
is the cost of buying a Vscan, amounting to a total of 
£12,300 (€14,181; $17,517).
Formal, hospital-based scans
The sonographer fee for a formal echocardiogram in our 
centre is £60 (€69; $85), and the hospital charges £265/scan 
(€306; $377). The cost for scanning eight patients who 
needed formal TTEs thus amounted to £480 (€553; $684) 
in fees only (8 × 60), or £2600 (€2998; $3703) including 
hospital charges (480 + 265 × 8 = 480 + 2120 = 2600).
Total cost
The cost of this study was therefore £12,300 + £480 = 
£12,780 (€14,734; $18,201 (i.e. £128/€148/$182 per 
patient)) if we consider only the physiologist fees for the 
extra formal TTEs in hospital or £12,300 + £2600 = £14,900 
(€17,186; $21,221 (i.e. £149/€172/$212 per patient) if we 
include the total charge levied by the hospital for the 
extra TTEs.
Discussion
In a study of 100 consecutive elderly subjects attending 
a primary care centre without a formal, pre-existing 
diagnosis of valve disease, a detailed grey-scale and colour 
flow mapping examination performed by an accredited 
sonographer using a Vscan hand-held ultrasound scanner 
Table 2 Echocardiographic findings: valve pathology.
Frequency/%
Aortic stenosis
 No 48
 Mild 19
 Moderate 4
 Severe 1
 Aortic sclerosis 28
Aortic regurgitation
 No 76
 Mild 24
Mitral regurgitation
 No 9
 Mild 83
 Moderate 6
 Severe 2
 Total 100
Table 3 Aortic valve leaflet restriction and calcification 
scores, means (s.d.).
AV Restriction score Calcification score
Normal 1.82 (1.13) 2.47 (0.5)
Aortic sclerosis 2.15 (0.98) 2.67 (0.48)
Mild AS 2.98 (1.20) 2.75 (0.52)
Moderate AS 5.53 (0.57) 3.67 (0.57)
Severe AS 6 4
There was one case of severe AS. P < 0.05 for all degrees of AS vs normal.
Table 4 Aortic valve pathology: outcomes and concordance 
of Vscan finding with formal TTE.
S/N Gender Age AS – Vscan TTE AS – TTE
29 M 78 Moderate N N/A
34 M 77 Moderate Y Moderate; f/u in VC
40 M 76 Moderate N N/A
46 F 81 Moderate Y Moderate; f/u in VC
89 F 76 Severe Y Severe; AVR
AS, aortic stenosis; AVR, aortic valve replacement; f/u, follow-up; N, no; N/A, 
not available (refused); S/N, study number; VC, valve clinic; Y, yes.
Table 5 Mitral valve pathology: outcomes and concordance 
of Vscan findings with formal TTE.
S/N Gender Age MR – Vscan TTE MR – TTE
11 F 77 Moderate Y Mild/moderate; discharged
17 F 80 Severe Y Severe; refused f/u
22 M 79 Moderate Y Mild; died – non-cardiac 
cause
61 F 75 Moderate Y Moderate; f/u in VC
64 M 77 Moderate N N/A
69 M 75 Moderate N N/A
70 M 77 Moderate N N/A
74 F 76 Severe Y Severe; MV repair
MR, mitral regurgitation; MV, mitral valve; VC, valve clinic.
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identified left-sided valve pathology of at least moderate 
severity in 13%. Two patients had valve intervention 
based on the findings in the screening study, and three are 
now under follow-up with the valve clinic in the tertiary 
centre; a significant proportion refused formal TTE in 
the hospital.
Comparison with other VHD screening studies
There is a significant literature concerning the use of 
POCUS and/or of limited scanning protocols for limiting 
the use of formal outpatient TTE, for elucidating heart 
murmurs or for screening for valve disease (20, 21, 22, 
23, 24). According to Fabich et al. (23): “Structural heart 
disease may be missed using clinical examination alone 
and limited echocardiograms or ‘quick-scans’ may be 
a way to improve rates of detection”. In a population 
>75 years of age “there were 163 ‘quick scans’ indicated, 
which were normal in 80 (49%), mildly abnormal in 67 
(41%) and significantly abnormal in 16 (10%)”, leading 
to the conclusion that ‘quick scans’ can detect clinically 
unexpected pathology. These results are consistent with 
a global move to use the hand-held ultrasound machine 
as an extension of the clinical examination (23).
Lindekleiv et  al. (24) report that echocardiographic 
screening of middle-aged participants in the longitudinal 
Tromso heart study did pick up unexpected pathologies 
but had no impact on mortality during medium-term 
follow-up. Potential reasons for this finding may include 
better health care in a rich, small nation (patients with 
valve disease are identified effectively by standard clinical 
practice, without the need for additional screening 
programmes) as well as the younger age of participants, 
with screening intercepting valve disease at an earlier 
stage in its natural progression.
By facilitating timely intervention, screening may 
have a potential for significant savings and improved 
outcomes: Approximately 45% of valve interventions are 
performed on unstable patients (25, 26), who necessitate 
longer, costlier stays in hospital (25) and who have 
increased mortality. Reducing the number of urgent and 
emergency operations would lead to cost savings and 
better survival.
Another feature of our study is the participation of an 
experienced, BSE-accredited sonographer performing as 
complete a scan as possible using the Vscan in a primary 
care setting. Many previous reports on Vscan have used 
‘echo-naïve’ operators, such as medical students, nurses 
or cardiologists in training, performing focused scans after 
minimal training and have demonstrated good sensitivity 
and specificity for the Vscan for limited, specific diagnoses 
(including screening for AS (27)), when compared to high-
end scanners operated by experts. Our aim was different 
and is part of our current attempts at exploring and 
developing new models of cardiac care in the community.
Nkomo et al. (4) pooled population-based studies to 
obtain data for 11,911 subjects aged at least 18 years. They 
identified moderate or severe valve disease in 615, with 
an increase in the frequency with age, from 0.7% (95% 
CI 0.5–1.0) in 18–44 year-olds to 13.3% (11.7–15.0) in the 
75 years and older group (P < 0.0001).
Marciniak et al. (28) studied 79,043 patients who were 
referred to a community open-access echocardiography 
service over 10  years for suspected heart failure. More 
than a third of the subjects – 29,682 patients (37.5%) – 
had mild, 8983 (11.3%) had moderate and 2134 (2.7%) 
had severe valve disease (total prevalence of clinically 
significant VHD 14%). The prevalence of AS, regurgitation, 
mitral stenosis and regurgitation was 10, 8.4, 1 and 
12.5% respectively.
Figure 1
Parasternal long-axis Vscan image of severe AS, obtained on (A) a high-end scanner and (B) on Vscan. Parasternal short-axis image of severe AS obtained 
on (C) Vscan and (D) on a high-end scanner.
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Eveborn et  al. (29) performed three repeated 
comprehensive echocardiographic examinations (1994, 
2001 and 2008) of a random sample of 3273 participants 
in the Tromso heart study and found 164 subjects 
with AS. Prevalence consistently increased with age, 
from being 0.2% in the 50- to 59-year cohort to 
9.8% in the 80- to 89-year cohort, giving an incidence 
rate of 4.9‰/year.
Lindroos et  al. (30) performed TTE screening in 
501 elderly participants (75–76, 80–81 and 85–86  years 
of age) in the Helsinki Heart study and in 55 subjects 
recruited for the echocardiographic sub-study and found 
critical native valve stenosis (calculated aortic valve area 
Figure 2
Parasternal image of severe MR obtained on (A) a high-end scanner and 
(B) on Vscan.
Figure 3
Apical four-chamber image of moderate MR obtained on (A) a high-end 
scanner and (B) on Vscan.
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≤0.8 cm2 and velocity ratio ≤0.35) in 12 subjects (2.2%), 
of whom six were symptomatic and potentially eligible 
for AVR. All subjects with AV stenosis were in the three 
oldest age groups. The prevalence of critical AV stenosis 
was 2.9% (95% confidence interval 1.4–5.1%) in the 
group 75–86 years of age.
We think that our findings are hypothesis-generating 
and may initiate a rethink of the models of high-quality 
care for heart valve patients in the community.
We found a prevalence of 8% of ≥moderate MR, 
5% of ≥moderate AS (total prevalence 13%). The 
Ox-Valve study (5), which also recruited in a primary care 
setting, reported newly diagnosed ‘clinically significant 
(moderate or severe) VHD’ in 6.4% of participants, with 
4.9% of subjects having pre-existing VHD, giving a total 
population prevalence of moderate or severe VHD of 
11.3%. We found a higher prevalence of VHD than in 
the Ox-Valve study, probably due to a combination of 
factors. Our study group was older (mean age 79.8 years, 
73 years in Ox-Valve), which may increase the prevalence 
of VHD; it is also possible that Vscan mis-labelled cases 
that would not have been validated by a formal TTE in 
the tertiary centre, mainly for regurgitant lesions. In 
the Ox-Valve, patients only had hospital screening with 
high-end scanners.
Comparison of standard and HUD echocardiography
The accuracy of HUD for detecting cardiac pathology is 
good, when compared to standard TTE (31, 32, 33, 34, 35). 
In our small sample of patients with clinically relevant 
VHD by Vscan, formal TTE in the hospital confirmed the 
HUD finding in those with AS but in two patients with 
MR formal TTE downgraded the HHU findings. This may 
be an intrinsic limitation of HUD, as previous studies 
also reported a tendency to over-estimate regurgitant 
jet area (32).
Cost and implications for screening
Our unsophisticated, preliminary analysis suggests that 
costs of screening would not be prohibitive. It may be 
possible to reduce the costs even further, for instance by 
targeting the scans to groups at high risk for a specific 
pathology, using an abbreviated protocol for scanning or 
by teaching enthusiastic GPs to use the Vscan to screen for 
valve disease as part of the clinical exam of their patients. 
Importantly, it may be possible to offset some of the costs 
against savings associated with the positive impact of 
early detection and timely intervention for VHD.
Our study expands the boundaries of HUD usage 
beyond those delineated by the relevant EACVI guidelines 
(36), which recommend FoCUS TTE examinations by 
HUD as part of the clinical examination and which states 
they should not be reimbursed.
Detailed TTE using HUD
In the hands of an expert operator, the accuracy of 
contemporary HUD is comparable to that of high-end 
stationary scanners, with agreement coefficients ranging 
between 0.55 and 0.66 (33, 34, 35), albeit a large and 
systematic comparison of the diagnostic accuracy of 
comprehensive TTE by HUD vs high-end platforms (33) 
concluded that “HUD should not be used as a surrogate” 
for TTE with a high-end machine. Of note, magnifying 
the image to ‘fill-in’ a 21-inch computer screen improved 
the diagnostic accuracy of HUD in the only study that 
reported the comparison with reporting on the Vscan 
screen (35).
Rationale for reimbursement
The recommendation from EACVI not to reimburse 
HUD FoCUS exams does not cover our setting. We did 
not include HUD as part of a physical examination by 
a clinician, and we used a comprehensive TTE protocol 
as opposed to a focused or limited one; the only way to 
have an expert operator perform the scan is to pay them 
for it. It is likely that as technological progress expands 
the capabilities of HUD, other legitimate modes of its 
usage will become established, and our work is a step in 
that direction.
Limitations of the study
We cannot extrapolate our findings regarding the 
prevalence of valve disease to a wider population, but our 
results are in the same range as those of the much larger 
Ox-Valve study, which reinforces their validity, at least 
for an UK-based elderly population. We cannot guarantee 
that patients who took part in the study are representative 
of the population from which this cohort was sampled, 
but there is no reason to believe that patients attending 
the surgery on the days when scanning was performed 
were substantially different from those attending on other 
days. Ours was a pragmatic setup, and this was the most 
accessible sample in a non-academic context. We could 
have selected patients based on the presence of high risk 
for finding abnormalities on echo, but this had been done 
before, and did not address our aim, which was to get an 
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idea on the prevalence of valve disease in the elderly in 
our catchment area.
This study was designed, performed and written up in 
a single tertiary centre. In order to avoid any possibility of 
bias in the interpretation of the POCUS data, our studies 
were assessed in a core lab, which would not be available 
for routine clinical work. However, all the cases of 
significant valve regurgitation were clear-cut and obvious 
so we would expect similar accuracy for interpretation by 
an experienced sonographer, once studies with suboptimal 
quality are excluded from the analysis.
We cannot know how accurate our Vscan diagnoses 
were in those patients who refused to attend for 
formal TTEs in the tertiary centre but, at least for AS, 
the findings by Vscan were concordant with those 
by formal TTE. We did not set out to assess the right 
ventricle by POCUS because of its complex shape and 
limited visibility. We cannot rule out the possibility that 
patients who put themselves forward for screening may 
have been worried about symptoms of heart disease, 
which they had not yet reported. The costs are those 
provided by our hospital finance department, and may 
not be representative for other settings. We did not 
calculate costs for seeing the patients that were referred 
to the cardiology outpatient clinic because the clinics are 
reimbursed on a sessional rather than ‘per-patient seen’ 
basis. Our analysis of costs is basic and unsophisticated, 
but is hypothesis generating.
Conclusion
Using a pocket-sized scanner (Vscan) in a primary 
care setting identified at least five elderly patients 
who needed valve replacement or follow-up in a valve 
clinic, out of a cohort of 100 elderly subjects presenting 
without a prior diagnosis of heart valve disease, at a 
relatively low cost. A model of health care that includes 
echocardiographic screening for valve disease performed 
by accredited sonographers in patients above the age of 
70  years and using hand-held ultrasound scanners in 
primary practice may be viable and has a potential to 
reduce health care-associated costs which needs to be 
further investigated.
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